SynbioTech Introduces SYNMUE™ Probiotic for Immune Aging, Debuting at Probiota Americas 2026
SynbioTech's Revolutionary Probiotic SYNMUE™ for Immune Aging
Vancouver, BC, June 5, 2026: In a major advancement for healthy aging, SynbioTech has officially launched SYNMUE™, a clinically validated probiotic designed to address immunosenescence – the age-related decline in immune function. This exciting development is set to be showcased at Probiota Americas 2026, from June 8 to 10 in Vancouver, Canada. SynbioTech, a pioneer in biotechnology solutions, aims to connect with brand owners and distributors interested in science-backed innovations for healthy aging.
The Importance of Immune Health in Aging.
As people age, their immune systems become less effective, resulting in decreased Natural Killer (NK) cell activity, which is crucial for the body’s defense against infections and diseases. Recognizing this significant challenge, SynbioTech's recent clinical study provides groundbreaking insights into how their probiotic strain, Lactiplantibacillus plantarum LP28, enhances immune resilience, especially in older adults.
The double-blind, placebo-controlled study focused on adults aged 50 to 75 years old with a history of recurrent upper respiratory tract infections. Participants who received LP28 saw an impressive increase of up to 48% in NK cell cytotoxic activity, showcasing the potential of SYNMUE™ as a vital tool for improving immune performance in aging populations.
Scientifically Backed Benefits of SYNMUE™
Clinical Trial Achievements
This 12-week intervention demonstrated that those taking the probiotic experienced significant improvements in immune-related biomarkers, suggesting enhanced immune regulation and reduced inflammation. Key markers, including interleukin-12 and C-reactive protein, indicated a healthier immune response among those consuming LP28 compared to the placebo group, whose immune responses showed little to no change.
Additionally, participants taking SYNMUE™ reported a notably lower incidence of common colds, indicating that improvements in NK cell function may contribute to overall better health outcomes for older adults. These compelling results help solidify SYNMUE™ as a scientific and practical solution for age-related immune challenges.
A Growing Market Focused on Healthy Aging
The global market for immune health supplements was valued at over USD 35 billion in 2024 and is expected to surpass USD 76 billion by 2033. This growth reflects a pressing need for effective solutions as the population aged 65 and older is projected to double by 2050.
Despite the rising demand, few products specifically address immunosenescence. SynbioTech's SYNMUE™ stands out by targeting the decline of immune function with a systemically defined approach, focusing on restoring NK cell activity to combat the effects of aging on the immune system.
SYNMUE™ and TWK10®: A Comprehensive Aging Solution
Together with SYNMUE™, SynbioTech brings another core ingredient, TWK10®, aimed at enhancing muscle resilience. While SYNMUE™ primarily focuses on immune health, TWK10® has demonstrated significant benefits in muscle performance, strength, and recovery, further asserting SynbioTech's leadership in advancing aging solutions.
Both SYNMUE™ and TWK10® reflect the company’s commitment to developing microbiome-based solutions backed by scientific evidence aimed at enhancing healthspan.
Join SynbioTech at Probiota Americas 2026
Attendees at Probiota Americas will have the opportunity to delve into SynbioTech’s innovative products, including SYNMUE™. As part of the event’s scientific program, Dr. Hsiao-Wen Huang will present valuable research demonstrating how microbiome health can influence muscle strength and resilience. Aimed at brand owners and distributors, this session will underscore the critical importance of addressing multiple dimensions of healthy aging.
In closing, as the need for effective aging solutions continues to grow, SynbioTech’s advancements through SYNMUE™ and TWK10® are set to reshape how we understand and support healthy aging. The company's CEO, Sean Yang, encapsulated the vision by stating, "Through SYNMUE™ and TWK10®, we are building science-backed microbiome solutions designed to help people age stronger, stay resilient, and live better."
For more information about SynbioTech and to learn more about SYNMUE™, please visit www.synbiotech.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.